跳至主要内容
临床试验/EUCTR2011-000105-53-CZ
EUCTR2011-000105-53-CZ进行中(未招募)1 期

A Prospective Follow-Up Study of Children Aged 23 to 25 months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth

KV Pharmaceutical Co.0 个研究点目标入组 375 人开始时间: 2012年7月27日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
375

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Each subject must meet the following criteria to be enrolled in this study:
  • 1.Maternal enrollment which resulted in a live birth in the 17P Efficacy Trial: A Multi-center, Randomized, Double-blind Study of Hydroxyprogesterone Caproate Injection, 250 mg/mL, Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery.
  • 2.During their involvement in the above protocol, mothers must have received at least one dose of study drug (Safety population).
  • 3.Children between 22 and 25 months of age adjusted for gestational age.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 375
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Subjects meeting any of the following criteria will be excluded from the study:
  • 1.There is no parent/legal guardian available to sign an informed consent.
  • 2.Born to women who are unblinded to study group assignment.

研究者

发起方
KV Pharmaceutical Co.

相似试验